Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Carcinoma, Hepatocellular 1

Interventions

Rituximab 52Cyclophosphamide 42fludarabine phosphate 41Peripheral Blood Stem Cell Transplantation 41Whole-Body Irradiation 26Mycophenolic Acid 25Cyclosporine 21Bortezomib 21Dexamethasone 19Busulfan 18Tacrolimus 17Etoposide 17Filgrastim 15Antilymphocyte Serum 14Methotrexate 13Melphalan 13ibrutinib 12Radiotherapy 11Calcium Dobesilate 9Sirolimus 8Lenalidomide 8Cyclosporins 8Methylprednisolone 7Flow Cytometry 7Everolimus 7Carboplatin 7ibritumomab tiuxetan 6zanubrutinib 5fludarabine 5Transplantation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Waldenstrom Macroglobulinemia × Pharmacokinetics × Clear all
NCT00989586 2017-02-06

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Completed
35 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡